ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 878

Significance of Interstitial Pneumonitis in Microscopic Polyangiitis

Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA, interstitial lung disease and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Microscopic polyangiitis (MPA) is often associated with lung involvement, including alveolar hemorrhage and interstitial pneumonitis (IP). Clinical characteristics of IP in MPA have not been well described. The aim of this study was to determine the prevalence and clinical course of IP in MPA.

Methods: We retrospectively identified MPA patients at a tertiary medical center in Japan between 2002-2014. MPA patients with positive perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) who presented with renal involvement, including glomerulonephritis, acute and chronic renal failure, or lung disease such as alveolar hemorrhage or IP were selected. Data were collected on clinical features, medications, radiographic imaging (chest X-ray and computed tomography), and clinical outcome

Results: We identified 39 Japanese patients with MPA (Table). Median age was 69 (16-87); 51% were female; median observation period was 33 months (range 3-158). Among 27/39 (69%) who had IP, IP preceded diagnosis of MPA in 9 (33%), was seen upon diagnosis in 15 (56%), and occurred after diagnosis in 3 (11%). IP was not diagnosed in 33% of patients with MPA, over a median observation period of 74 months (range 45-138). Thirty-seven (95%) patients were treated with steroids or immunosuppressants. Acute exacerbation of IP was seen in 4 (15 %), and no radiographic change in 9 (33%) or minimal worsening of IP without clinical significance in14 (52%) on was found. All-cause mortality or death due to pulmonary complication in MPA did not differ between subjects with or without IP.

Conclusion: IP often precedes other manifestations of MPA. Clinical characteristics and outcomes are similar to those without IP. 

Table. Clinical Characteristics of Microscopic Polyangiitis, by Interstitial Pneumonitis status.
Clinical characteristics Interstitial pneumonitis present Interstitial pneumonitis absent P
n 27 12
Age, years (range) 70 (56-87) 68 (15-86) 0.16
Female (n, %) 14 (52) 6 (50) 1
Observation period, months, median(range) 33 (3-159) 31 (18-77) 0.76
Tobacco (n, %) 15 (56) 8 (67) 0.73
Renal involvement (n, %) 23 (85) 12 (100) 0.29
Fever (n, %) 15 (56) 5 (42) 0.5
Skin involvement (n, %) 1 (4) 3 (25) 0.08
Peripheral neuropathy  (n, %) 3 (11) 2 (17) 0.63
Alveolar hemorrhage (n, %) 5 (19) 4 (33) 0.42
Steroids (n, %) 25 (93) 12 (100) 1
Immunosuppressants* (n, %) 17 (63) 6 (50) 0.5
All-cause mortality (n, %) 12 (44) 3 (25) 0.31
Deaths due to pulmonary complication (n, %) 6 (22) 2 (17) 1
*Cyclophosphamide, azathioprine, cyclosporine, methotrexate and rituximab.

Disclosure: K. Nakanishi, None; M. Kinjo, None.

To cite this abstract in AMA style:

Nakanishi K, Kinjo M. Significance of Interstitial Pneumonitis in Microscopic Polyangiitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/significance-of-interstitial-pneumonitis-in-microscopic-polyangiitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/significance-of-interstitial-pneumonitis-in-microscopic-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology